Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that, for the second consecutive year, it has been recognized as a Top Workplace for 2015.

“This recognition is a testament to the passion and dedication of our 350 SuperNovas,” said Stanley C. Erck, President and CEO. “Our employees exemplify the excellence and commitment necessary to make an impact on global health. I come to work every day excited to work with each and every one of them.”

The Washington Post Top Workplaces are determined solely on employee feedback via an employee survey conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.

Jill Hoyt, Vice President, Human Resources, said, “It is an honor to receive this recognition for the second year in a row. This award underscores Novavax’ commitment to creating a culture where our employees are a key part of innovative solutions, cutting-edge technology and shared success.” (Original Source)

Shares of Novavax closed yesterday at $9.53. NVAX has a 1-year high of $9.95 and a 1-year low of $3.92. The stock’s 50-day moving average is $8.67 and its 200-day moving average is $7.89.

On the ratings front, Novavax has been the subject of a number of recent research reports. In a report issued on April 9, MLV & Co. analyst Vernon Bernardino maintained a Buy rating on NVAX, with a price target of $14, which implies an upside of 46.9% from current levels. Separately, on March 27, Citigroup’s Joel Beatty assigned a Buy rating to the stock and has a price target of $10.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Joel Beatty have a total average return of -0.3% and 65.5% respectively. Bernardino has a success rate of 45.2% and is ranked #2799 out of 3635 analysts, while Beatty has a success rate of 100.0% and is ranked #2027.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.